ATE555078T1 - Verfahren und zwischenprodukte - Google Patents

Verfahren und zwischenprodukte

Info

Publication number
ATE555078T1
ATE555078T1 AT01975197T AT01975197T ATE555078T1 AT E555078 T1 ATE555078 T1 AT E555078T1 AT 01975197 T AT01975197 T AT 01975197T AT 01975197 T AT01975197 T AT 01975197T AT E555078 T1 ATE555078 T1 AT E555078T1
Authority
AT
Austria
Prior art keywords
intermediate products
products
Prior art date
Application number
AT01975197T
Other languages
English (en)
Inventor
Ann Eldridge
Johann Hiebl
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE555078T1 publication Critical patent/ATE555078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AT01975197T 2000-09-12 2001-09-12 Verfahren und zwischenprodukte ATE555078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12
PCT/US2001/028443 WO2002022554A1 (en) 2000-09-12 2001-09-12 Process and intermediates

Publications (1)

Publication Number Publication Date
ATE555078T1 true ATE555078T1 (de) 2012-05-15

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01975197T ATE555078T1 (de) 2000-09-12 2001-09-12 Verfahren und zwischenprodukte

Country Status (11)

Country Link
US (2) US6570024B2 (de)
EP (1) EP1322597B1 (de)
JP (1) JP4886961B2 (de)
AR (1) AR030612A1 (de)
AT (1) ATE555078T1 (de)
AU (1) AU2001294549A1 (de)
CY (1) CY1112871T1 (de)
DK (1) DK1322597T3 (de)
ES (1) ES2383792T3 (de)
PT (1) PT1322597E (de)
WO (1) WO2002022554A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
EP2437785B1 (de) 2009-06-04 2015-02-25 Novartis AG Verfahren zur identifizierung von stellen für igg-konjugation
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2714737A1 (de) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17)-bindende proteine
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP3068892A4 (de) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalente antigenbindende konstrukte zum targeting von egfr und/oder her2 und verwendungen davon
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
EP3956332B1 (de) * 2019-04-18 2023-02-22 Indena S.p.A. Diasteroselektives verfahren zur herstellung von thiol- oder disulfidhaltigen maytansinoidestern und zwischenprodukten davon
CA3220227A1 (en) 2021-05-28 2022-12-01 Matthew Bruce Combination therapies for treating cancer
EP4412713A1 (de) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Kombinationstherapien zur behandlung von krebs
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS61112042A (ja) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk 架橋試薬として適当な化合物
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (ja) * 1998-07-17 2003-05-19 大日本製薬株式会社 スルトプリド誘導体及び抗スルトプリド抗体
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
US6570024B2 (en) 2003-05-27
DK1322597T3 (da) 2012-07-02
US6884874B2 (en) 2005-04-26
AR030612A1 (es) 2003-08-27
CY1112871T1 (el) 2016-04-13
EP1322597B1 (de) 2012-04-25
EP1322597A1 (de) 2003-07-02
US20040014980A1 (en) 2004-01-22
EP1322597A4 (de) 2005-10-19
WO2002022554A1 (en) 2002-03-21
PT1322597E (pt) 2012-06-01
AU2001294549A1 (en) 2002-03-26
ES2383792T3 (es) 2012-06-26
US20020156318A1 (en) 2002-10-24
JP4886961B2 (ja) 2012-02-29
JP2004509094A (ja) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE283273T1 (de) Hemisynthetisches verfahren und dessen zwischenprudukte
DE60140895D1 (de) Zusammensetzung und verfahren
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
CY2008006I1 (el) Παραγωγα τροπανιου χρησιμα στη θepαπευτικη
DE60129522D1 (de) Gipszusammensetzungen und dazugehörende verfahren
FI19992360L (fi) Tuote ja menetelmä sen valmistamiseksi
DE60115902D1 (de) Osteoimplantat und verfahren zu seiner herstellung
DE60134496D1 (de) Polyesterverfahren
DE60138648D1 (de) Modulare atemgeräte und verfahren zum umbau derselben
DE60112988D1 (de) Kabelbaum und Herstellungsverfahren
DE59913180D1 (de) Produktebestellungsverfahren und system
DE60100770D1 (de) Doppelbahniger Förderbandreinigungsapparat und Verfahren
ATA10852001A (de) Bauelement und verfahren zu seiner herstellung
DE60229770D1 (de) Reibungsreduzierende zusammensetzung und verfahren
DE60134540D1 (de) Töchiometrie aufweisender isolierschicht und verfahren zur herstellung
ATE286658T1 (de) Teigformmaschine und verfahren
DE60017012D1 (de) Orginalitätsverschluss und Herstellungverfahren
DE60116486D1 (de) Gallengangstent und verfahren zu seiner herstellung
DK1322597T3 (da) Fremgangsmåde og intermediære
DE69904731D1 (de) Feinzerkleinerer und feinzerkleinerungsverfahren
ATE322174T1 (de) Gefrorene süsswaren und herstellungsverfahren
DE60106372D1 (de) Redox System und Verfahren
EP1347866A4 (de) Holzprodukte und verfahren zur herstellung derselben
EP1299337A4 (de) Hydroxyphenstatin und seine promedikamente
DE60208700D1 (de) Schälgerät und zugehörige verfahren